(E)-3,4,5-trimethoxy-N-(2-methyl-3-phenylallyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3,4,5-trimethoxy-N-(2-methyl-3-phenylallyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide
• 英文别名: 3,4,5-trimethoxy-N-(2-methyl-3-phenyl-allyl)-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]benzamide；3,4,5-trimethoxy-N-[(E)-2-methyl-3-phenylprop-2-enyl]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]benzamide
• 化学式: C₂₇H₃₆N₂O₄
• 分子量: 452.594
• InChiKey: PYZMBELGBYJDBI-CAPFRKAQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  反式-alpha-甲基肉桂醛 在 sodium tetrahydroborate 、 magnesium sulfate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 99.17h， 生成 (E)-3,4,5-trimethoxy-N-(2-methyl-3-phenylallyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide
  参考文献：
  名称：

  Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists

  摘要：

  The chemokine receptor CXCR7 is an atypical G protein-coupled receptor as it preferentially signals through the beta-arrestin pathway rather than through G proteins. CXCR7 is thought to be of importance in cancer and the development of CXCR7-targeting ligands is of huge importance to further elucidate the pharmacology and the therapeutic potential of CXCR7. In the present study, we synthesized 24 derivatives based on a compound scaffold patented by Chemocentryx and obtained CXCR7 ligands with pK(i) values ranging from 5.3 to 8.1. SAR studies were supported by computational 3D Fingerprint studies, revealing several important affinity descriptors. Two key compounds (29 and 30, VUF11207 and VUF11403) were found to be high-potency ligands that induce recruitment of beta-arrestin2 and subsequent internalization of CXCR7, making them important tool compounds in future CXCR7 research. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.02.041

文献信息

• Inhibitors of human tumor-expressed CCXCKR2
  申请人：——

  公开号：US20040171655A1

  公开（公告）日：2004-09-02

  Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

  本发明揭示了含有有机化合物或其盐的药物组合物，其作为SDF-1或I-TAC趋化因子的调节剂。这些化合物和组合物在癌症治疗中非常有用，特别是在抑制癌细胞增殖、生长和转移方面。本发明还揭示了干扰SDF-1和/或I-TAC与CCXCKR2受体结合以及使用本发明的化合物和药物组合物治疗癌症的方法。
• INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2
  申请人：Melikian Anita

  公开号：US20100144720A1

  公开（公告）日：2010-06-10

  Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

  本发明涉及含有有机化合物或其盐的制药组合物，其作为SDF-1或I-TAC趋化因子的调节剂。这些化合物和组合物在癌症治疗中特别是在抑制癌症增殖、生长和转移方面具有用途。本发明还揭示了干扰SDF-1和/或I-TAC与CCXCKR2受体结合以及使用本发明的化合物和制药组合物治疗癌症的方法。
• Methods and Compositions For Modulating Angiogenesis
  申请人：Burns Jennifer

  公开号：US20100247540A1

  公开（公告）日：2010-09-30

  The present invention provides method and compositions for modulating angiogenesis.

  本发明提供了一种调节血管生成的方法和组合物。
• [EN] INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR<br/>[FR] INHIBITEURS DE CCXCKR2 D'EXPRESSION TUMORALE HUMAINE
  申请人：CHEMOCENTRYX

  公开号：WO2004058705A3

  公开（公告）日：2004-08-19
• INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR
  申请人：ChemoCentryx, Inc.

  公开号：EP1606251B1

  公开（公告）日：2009-04-08